Pre-made Sotigalimab biosimilar ( Whole mAb, anti-CD40 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-529
Anti-CD40 therapeutic antibody (Pre-made Sotigalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Sotigalimab is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. Sotigalimab targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD40 therapeutic antibody (Pre-made Sotigalimab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Pancreatic cancer;Metastatic cancer;Non-small cell lung cancer;Renal cell carcinoma;Gastric adenocarcinoma;Soft-tissue sarcoma;Esophageal carcinoma;Rectal cancer;Malignant melanoma|
|Conditions Discontinued||Brain cancer;Glioma;Solid tumours|